检索结果-南通市图书馆

Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients

引用

World Journal of Clinical Oncology 2024年第7期15卷 848-858页

作者： Naveed Syed Ashish Vittalrao Chintakuntlawar Deepti Vilasini Aisha Mohamed Al Salami Riad Al Hasan Imrana Afrooz kanishka uttam chandani Ashok uttam chandani Aref Chehal Department of Hematology and Oncology Sheikh Shakbout Medical CityAbu Dhabi 11001United Arab Emirates Department of Oncology Mayo ClinicRochesterNY 790339United States Department of Oncology Sheikh Shakbout Medical CityAbu Dhabi 11001United Arab Emirates Clinical Research Sheikh Shakbout Medical CityAbu Dhabi 11001United Arab Emirates Department of Internal Medicine Landmark Medical CenterRhode IslandRI 02895United States

BACKGROUND Poly(ADP-ribose)polymerase inhibitors(PARPis)are approved as first-line therapies for breast cancer gene(BRCA)-positive,human epidermal growth factor receptor 2-negative locally advanced or metastatic breast *** are also effective for new and recurrent ovarian cancers that are BRCA-or homologous recombination deficiency(HRD)-***,data on these mutations and PARPi use in the Middle East are *** To assess BRCA/HRD prevalence and PARPi use in patients in the Middle East with breast/ovarian *** This was a single-center retrospective study of 57 of 472 breast cancer patients tested for BRCA mutations,and 25 of 65 ovarian cancer patients tested for *** adult patients participated in at least four visits to the oncology service at our center between August 2021 and May *** were summarized using descriptive statistics and compared using counts and *** to treatment was assessed using Response Evaluation Criteria in Solid Tumors *** Among the 472 breast cancer patients,12.1%underwent BRCA testing,and 38.5%of 65 ovarian cancer patients received HRD *** mutations were found in 25.6%of the tested patients:26.3%breast cancers had germline BRCA(gBRCA)mutations and 24.0%ovarian cancers showed ***,40.0%of gBRCA-positive breast cancers and 66.0%of HRD-positive ovarian cancers were Middle Eastern and Asian patients,*** treatment was used in 5(33.3%)gBRCA-positive breast cancer patients as first-line therapy(n=1;7-months progression-free),for maintenance(n=2;>15-months progression-free),or at later stages due to compliance issues(n=2).Four patients(66.6%)with HRD-positive ovarian cancer received PARPi and all remained *** Lower testing rates but higher BRCA mutations in breast cancer were *** reflected United Arab Emirates demographics,with breast cancer in Middle Eastern and ovarian cancer in Asian patients.

关键词： Homologous recombination repair BRCA1 BRCA2 Homologous recombination deficiency Ovarian cancer Breast cancer Poly(ADP-ribose)polymerase inhibitors Olaparib DNA double-strand breaks

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：